# Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

> **NCT00495872** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 204 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Erlotinib
- **DRUG:** Lapatinib
- **DRUG:** Lenalidomide
- **DRUG:** Sorafenib
- **DRUG:** Sunitinib
- **DRUG:** Valproic Acid

## Key facts

- **NCT ID:** NCT00495872
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2012-10
- **Final completion:** —
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2012-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00495872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00495872, "Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00495872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*